-88%

est. 2Y upside i

HealthcareSeed

Vibe Bio is a biotech company composed of patients, scientists, and partners that is governed & funded by a crypto token.

Rank

#1218

Sector

Biotechnology

Est. Liquidity

~6Y

Data Quality

Data: Medium

Vibe Bio presents a moderate upside opportunity for a job seeker, with an estimated current valuation of $80M based on its $12M seed funding and early revenue.

Last updated: March 10, 2026

Bull (20%)+300%

Vibe Bio's AI platform (VibeOne) successfully identifies and accelerates multiple high-potential rare disease drug candidates, leading to successful clinical trial advancements and lucrative partnerships or acquisitions of its portfolio companies. This drives Vibe Bio's valuation to $320M, a 4x return, as its unique DAO model gains significant traction in funding overlooked diseases.

Base (45%)+100%

Vibe Bio continues to make steady progress, with one or two portfolio drug programs advancing to mid-stage clinical trials and attracting further investment. The company establishes itself as a niche player in rare disease drug development, growing its revenue through equity stakes in successful ventures. This leads to a valuation of $160M, a 2x return, reflecting solid execution but without breakthrough successes.

Bear (35%)-80%

Vibe Bio faces significant challenges in advancing its drug pipeline due to high regulatory hurdles, intense competition from larger biopharma companies, or a failure of its DAO model to consistently attract sufficient funding for promising assets. This results in a down round or an exit at a significantly reduced valuation of $16M, wiping out most common stock value given the $12M liquidation preference.

Est. time to liquidity~6.0 years

Preference Stack Risk

moderate

Investors hold $12M in liquidation preferences. In an $80M exit, common shareholders would theoretically receive $68M.

Dilution Risk

high

As an early-stage biotech company with high capital intensity, Vibe Bio will likely require multiple significant funding rounds, leading to substantial future dilution for current equity holders.

Secondary Liquidity

none

Given its early stage and private status, there is currently no active secondary market or tender offer for Vibe Bio's equity.

Questions to Ask at the Interview

Strategic questions based on Vibe Bio's data — designed to show you've done your homework.

  • 1

    “Given the high capital intensity of drug development, how does Vibe Bio plan to secure future funding rounds beyond its initial seed capital, especially for advancing multiple drug candidates through costly clinical trials?”

  • 2

    “How does Vibe Bio's unique DAO model truly differentiate it from traditional biotech venture capital firms, and what mechanisms are in place to ensure consistent community engagement and funding for its portfolio companies?”

  • 3

    “Considering the long development timelines in rare disease therapeutics, what is the company's projected timeline for a liquidity event (e.g., IPO or acquisition) for employees holding equity, and what milestones are critical to achieving that?”

Community

Valuation Sentiment

Our model estimates -88% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.